Cart
sales@molnova.com
Topotecan
CAS No. 123948-87-8
Topotecan( SKF 104864A | NSC 609669 )
Catalog No. M20386 CAS No. 123948-87-8
Topotecan is a Topoisomerase I inhibitorand is an antineoplastic agent used to treat ovarian cancer that works by inhibiting DNA topoisomerases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 43 | In Stock |
|
| 5MG | 30 | In Stock |
|
| 10MG | 43 | In Stock |
|
| 25MG | 72 | In Stock |
|
| 50MG | 108 | In Stock |
|
| 100MG | 160 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTopotecan
-
NoteResearch use only, not for human use.
-
Brief DescriptionTopotecan is a Topoisomerase I inhibitorand is an antineoplastic agent used to treat ovarian cancer that works by inhibiting DNA topoisomerases.
-
DescriptionTopotecan is a Topoisomerase I inhibitorand is an antineoplastic agent used to treat ovarian cancer that works by inhibiting DNA topoisomerases.
-
In VitroTopotecan obviously inhibits proliferation of human glioma cells and glioma stem cells (GSCs) in a dose- and time-dependent manner. Topotecan (0-40 μM) obviously inhibits the cell viability compared with the control groups, in a dose-dependent manner.Topotecan shows anti-proliferation activity against U251, U87, GSCs-U251 and GSCs-U87 cells, with IC50 values of 2.73±0.25, 2.95±0.23, 5.46±0.41, and 5.95±0.24 μM, respectively.
-
In VivoNUB-7 metastatic model, the animals belonging to all the 4 groups are sacrificed after 14 days treatment. Compared with the control, Low dose metronomic (LDM) Topotecan (TP) and TP+Pazopanib (PZ) liver weights are significantly lower in TP+PZ-treated animals, compared with PZ. Microscopic tumors are visible in the livers of mice belonging to all the groups except TP+PZ confirming the ability of TP+PZ to control liver metastasis. Topotecan (0.5, 1.0, and 1.5 mg/kg; Orally, daily) causes greater reduction in microvascular density in an ovarian cancer model, but the mice treated with 1.5 mg/kg daily, oral Topotecan show decreased food intake, and a lesser antitumor effect.
-
SynonymsSKF 104864A | NSC 609669
-
PathwayCell Cycle/DNA Damage
-
TargetTopoisomerase
-
RecptorEukaryotic topoisomerase I
-
Research AreaCancer
-
Indicationsmall cell lung Cancer cervical Cancer
Chemical Information
-
CAS Number123948-87-8
-
Formula Weight421.45
-
Molecular FormulaC23H23N3O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:84 mg/mL (199.31 mM)
-
SMILESCC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Feng-Lei Z Ping W Yun-Hui L et al. Topoisomerase I Inhibitors Shikonin and Topotecan Inhibit Growth and Induce Apoptosis of Glioma Cells and Glioma Stem Cells[J]. PLoS ONE 2013 8(11):e81815-.
molnova catalog
related products
-
Etoposide
Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
-
Zoliflodacin
Zoliflodacin (ETX0914, AZD0914) is a new bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus (MIC90: 0.25 μg/mL).
-
Exatecan Mesylate
Exatecan Mesylate is a DNA topoisomerase I inhibitor (IC50: 2.2 μM, 0.975 μg/mL).Exatecan Mesylate (DX-8951f) significantly inhibits the proliferation of several cancer cell lines, with mean GI50s of 2.02 ng/mL, 2.92 ng/mL, 1.53 ng/mL, and 0.877 ng/mL for breast cancer cells, colon cancer cells, stomach cancer cells and lung cancer cells, respectively.
